Dupixent (dupilumab)

For Community

For Fellows and Trainees

For Health Professionals

Posted 8 months ago

Sanofi Genzyme has made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) requesting reimbursement on the Pharmaceutical Benefits Scheme (PBS) for Dupixent® (dupilumab) for the treatment of severe atopic dermatitis in adult patients who are candidates for systemic treatment. The submission will be considered at the March 2020 PBAC meeting.

In the lead-up to the PBAC meeting, patients, families and healthcare professionals are invited to comment on any aspect of the medicines being considered. The period for comment closes on 12 February 2020.

Comments from individuals will be made available in summary to the sponsor of the application and the PBAC. The names of individuals will be removed. All comments from groups or organisations will be provided in a complete form to both the PBAC and the sponsoring organisation.

To lodge a comment, please go to the PBAC online submission form on the Department of Health website. This form is also available in hard copy on request from the PBAC Secretariat on 02 6289 7099.

More information about this process can also be found on the Department of Health website.